Browsing by Author "Vural, Filiz"

Filter results by typing the first few letters
Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Autologous Hematopoietic Progenitor Cell Mobilization and Collection in Adult Patients Presenting with Multiple Myeloma and Lymphoma: A Position-Statement from The Turkish Society of Apheresis (TSA)
    (2017) Tekgunduz, Emre; Arat, Mutlu; Goker, Hakan; Ozdogu, Hakan; Kaynar, Leylagul; Cagirgan, Seckin; Erkurt, Mehmet Ali; Vural, Filiz; Kiki, Ilhami; Altuntas, Fevzi; Demirkan, Fatih; https://orcid.org/0000-0002-8902-1283; 29153306; AAD-5542-2021
    Autologous hematopoietic cell transplantation (AHCT) is a routinely used procedure in the treatment of adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and relapsed/refractory settings. Successful hematopoietic progenitor cell mobilization (HPCM) and collection are the rate limiting first steps for application of AHCT. In 2015, alinost 1700 AHCT procedures have been performed for MM, HL and NHL in Turkey. Although there are recently published consensus guidelines addressing critical issues regarding autologous HPCM, there is a tremendous heterogeneity in terms of mobilization strategies of transplant centers across the world. In order to pave the way to a more standardized HPCM approach in Turkey, Turkish Society of Apheresis (TSA) assembled a working group consisting of experts in the field. Here we report the position statement of TSA regarding autologous HPCM mobilization strategies in adult patients presenting with MM and lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    Current Practice of Autologous Hematopoietic Progenitor Cell Mobilization in Adult Patients with Multiple Myeloma And Lymphoma: The Results of A Survey From Turkish Hematology Research And Education Group (Threg)
    (2017) Tekgunduz, Emre; Demirkan, Fatih; Vural, Filiz; Goker, Hakan; Ozdogu, Hakan; Kiki, Ilhami; Aydogdu, Ismet; Kaynar, Leylagul; Erkurt, Mehmet Ali; Cagirgan, Seckin; Besisik, Sevgi; Dagdas, Simten; Koca, Ebru; Kadikoylu, Gurhan; Gunduz, Eren; Yilmaz, Mehmet; Bekoz, Huseyin; Ural, Ali Ugur; Basturk, Abdulkadir; Arat, Mutlu; Albayrak, Murat; Ozturk, Erman; Akyol, Alev; Bolaman, Ali Zahit; Nevruz, Oral; Ozkan, Hasan Atilla; Ozgur, Gokhan; Altuntas, Fevzi; 29153305
    Autologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and/or relapsed/refractory disease settings. Although there are recently published consensus guidelines addressing critical issues regarding autologous hematopoietic progenitor cell mobilization (HPCM), mobilization strategies of transplant centers show high variability in terms of routine practice. In order to understand the current institutional policies regarding HPCM in Turkey and to obtain the required basic data for preparation of a national positional statement on this issue, Turkish Hematology Research and Education Group (ThREG) conducted a web-based HPCM survey. The survey was designed to include multiple-choice questions regarding institutional practice of HPCM in adults presenting MM, HL, and NHL. The representatives of 27 adult HCT centers participated to the study. Here we report the results of this survey shedding light on the real world experience in Turkey in terms of autologous HPCM mobilization strategies in patients presenting with MM and lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish Experience
    (2021) Yilmaz, Ergun; Soyer, Nur; Seval, Guldane Cengiz; Bozdag, Sinem Civriz; Topcuoglu, Pervin; Unal, Ali; Kaynar, Lalegul; Ozgur, Gokhan; Sucak, Gulsan; Goker, Hakan; Velet, Mustafa; Ozdogdu, Hakan; Yilmaz, Mehmet; Kaya, Emin; Salim, Ozan; Deveci, Burak; Karadogan, Ihsan; Saydam, Guray; Sahin, Fahri; Vural, Filiz; 34057336
    Objective: Although inhibition of the complement system at different steps is a promising therapy modality in patients with paroxysmal nocturnal hemoglobinuria (PNH), allogeneic hematopoietic stem cell transplantation (HCT) is still the only curative therapy, especially for patients with intractable hemolysis or bone marrow failure. The aim of this study is to evaluate the outcomes of allogeneic HCT in PNH patients with aplastic anemia (PNH-AA) or without. Materials and Methods: Thirty-five PNH/PNH-AA patients who were treated with allogeneic HCT in 10 transplantation centers in Turkey were retrospectively analyzed. Results: Sixteen (45.7%) and 19 (54.3%) patients were diagnosed with classical PNH and PNH-AA, respectively. The median age of the patients was 32 (18-51) years. The 2-year overall survival (OS) rate and rate of graft-versus-host disease-free, failure-free survival (GFFS) was 81.2% and 78.1%, respectively. The 2-year OS in cases of classical PNH and PNH-AA was 81.3% and 79.9%, respectively (p=0.87), and 2-year GFFS in cases of PNH and PNH-AA was 79% and 76% (p=0.977), without statistical significance. The OS and GFFS rates also did not differ between transplantations with matched sibling donors (MSDs) and matched unrelated donors (MUDs). Conclusion: Allogeneic HCT with MSDs or MUDS is a good option for selected patients with classical PNH and PNH-AA. In particular, patients with debilitating and refractory hemolysis and patients with bone marrow failure might form an excellent group of candidates for allogeneic HCT.
  • No Thumbnail Available
    Item
    Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic transplantation: Retrospective multicenter study of Turkish hematology research and education group (THREG), updated data
    (2019) Soyer, Nur; Gunduz, Mehmet; Tekgunduz, Emre; Deveci, Burak; Ozdogu, Hakan; Sahin, Handan Haydaroglu; Turak, Esra Ermis; Okay, Mufide; Kuku, İrfan; Hindilerden, Ipek Yonal; Topcuoglu, Pervin; Altuntas, Feviz; Karadogan, Ihsan; Pehlivan, Mustafa; Unal, Ali; Goker, Hakan; Erkurt, Mehmet Ali; Besisik, Sevgi Kalayoglu; Vural, Filiz
  • No Thumbnail Available
    Item
    An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
    (2021) Sevindik, Omur Gokmen; Ozkurt, Zubeyde Nur; Boga, Can; Besisik, Sevgi Kalayoglu; Ipek, Yildiz; Geduk, Ayfer; Harmandali, Aybuke; Salihoglu, Ayse; Sahin, Handan Haydaroglu; Sonmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Yuksel, Meltem Kurt; Maral, Senem; Ekinci, Omer; Kirkizlar, Hakki Onur; Tekinalp, Atakan; Demir, Nazli; Merter, Mustafa; Saydam, Guray; Alacacioglu, Inci; Yegin, Zeynep Arzu; Kasar, Mutlu; Mastanzade, Metban; Ozsan, Guner Hayri